GH Research PLC (GHRS) stock
GHRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$18.25−0.02 (-0.11%)
Close on Nov 18, 2026Market cap $1.13BP/E –Yield –
GH Research operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
GH Research's operating income for the twelve months ending Jun 30, 2026 was -$71.49M. For fiscal 2025 it was -$60.72M. The highest annual figure on record is -$310.00K in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$60.72M | – |
| FY2024 | Dec 31, 2024 | -$50.31M | – |
| FY2023 | Dec 31, 2023 | -$41.22M | – |
| FY2022 | Dec 31, 2022 | -$30.55M | – |
| FY2021 | Dec 31, 2021 | -$15.10M | – |
| FY2020 | Dec 31, 2020 | -$446.00K | – |
| FY2019 | Dec 31, 2019 | -$310.00K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$19.46M | – |
| Q1 FY2026 | Mar 31, 2026 | -$18.75M | – |
| Q4 FY2025 | Dec 31, 2025 | -$16.72M | – |
| Q3 FY2025 | Sep 30, 2025 | -$16.57M | – |
| Q2 FY2025 | Jun 30, 2025 | -$14.70M | – |
| Q1 FY2025 | Mar 31, 2025 | -$12.73M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.94M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.62M | – |
| Q2 FY2024 | Jun 30, 2024 | -$13.22M | – |
| Q1 FY2024 | Mar 31, 2024 | -$11.53M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.16M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.72M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.93M | – |
| Q1 FY2023 | Mar 31, 2023 | -$10.42M | – |
| Q4 FY2022 | Dec 31, 2022 | -$9.17M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.63M | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.75M | – |
See a number that looks wrong?